Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 10/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | BIRC3 | Q13489 | 4/20 | 0.44 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358625 | 1.00 | XIAP (0.57) | XIAPKMT2ATSHRHPGDBIRC3 | |
| SCHEMBL14174381 | 0.94 | XIAP (0.58) | XIAPKMT2ATSHRHPGDBIRC3 | |
| SCHEMBL2213538 | 0.94 | XIAP (0.58) | XIAPKMT2ATSHRHPGDBIRC3 | |
| SCHEMBL2213541 | 0.94 | XIAP (0.58) | XIAPKMT2ATSHRHPGDBIRC3 | |
| SCHEMBL2212526 | 0.89 | XIAP (0.52) | XIAPKMT2ATSHRHPGDBIRC3 | |
| SCHEMBL2214177 | 0.89 | XIAP (0.52) | XIAPKMT2ATSHRHPGDBIRC3 | |
| SCHEMBL14174358 | 0.87 | XIAP (0.51) | XIAPKMT2ATSHRHPGDBIRC3 | |
| SCHEMBL2211611 | 0.87 | XIAP (0.51) | XIAPKMT2ATSHRHPGDBIRC3 | |
| SCHEMBL2211622 | 0.87 | XIAP (0.51) | XIAPKMT2ATSHRHPGDBIRC3 | |
| SCHEMBL2209669 | 0.87 | XIAP (0.56) | XIAPKMT2ATSHRHPGDBIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | claimed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | claimed |
| EP-2099769-A1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073305-A1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | claimed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | XIAP 1/4885KMT2A 4492/4885TSHR 4823/4885 |
| US-20100249405-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | XIAP 1/4885KMT2A 4492/4885TSHR 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.